Moderna Stock Soars 177 Percent on Melanoma Vaccine Trial, Then Gives Back a Quarter
Moderna and Merck announced Wednesday that their personalized mRNA cancer vaccine, paired with Merck’s immunotherapy Keytruda, hit its main goal in a Phase 3 trial…
Read More
Center
